ArticlePloS one2026

Comparison of outcomes of second-line durvalumab plus tremelimumab versus lenvatinib following first-line atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.

Chinatsu Nishioka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.